Inflazome Announces Acquisition by Roche
21.9.2020 09:00:00 EEST | Business Wire | Press release
Inflazome announced today that it has closed a share purchase agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) in which Inflazome’s shareholders received an upfront payment of €380 million, and are eligible to receive additional contingent payments to be made based on the achievement of certain predetermined milestones.
Inflazome was founded in 2016 by leading medical researchers Prof Matt Cooper (University of Queensland, Australia) and Prof Luke O’Neill (Trinity College Dublin, Ireland). The company is a leader in the development of inflammasome inhibitors.
The acquisition gives Roche full rights to Inflazome’s entire portfolio which is composed of clinical and preclinical orally available small molecule NLRP3 inhibitors. Roche intends to further develop NLRP3 inhibitors across a wide variety of indications with high unmet medical need.
Matt Cooper, Chief Executive Officer, Inflazome, commented: “We are delighted to close this deal with Roche, an outstanding pharmaceutical company with a broad commitment to multiple indications. With Inflazome now part of the Roche organization, Inflazome’s pioneering molecules are well positioned to be developed quickly and effectively so they can help patients suffering from debilitating diseases.”
Manus Rogan, Chairman and co-founding investor of Inflazome, said: “It has been a privilege to work alongside Matt, his team and my co-investors. The Company, which was established just four years ago, developed a portfolio of clinical and pre-clinical molecules with a lean, highly experienced team and limited invested capital.”
Lazard acted as financial advisor and Goodwin Procter and Byrne Wallace acted as legal counsel to Inflazome.
About Inflazome
Inflazome is a biotech company leading the development of orally available drugs to address clinical unmet needs in inflammatory diseases by targeting inflammasomes. Inflammasomes are understood to drive many chronic inflammatory conditions, from Parkinson’s and Alzheimer’s to asthma, inflammatory bowel disease, chronic kidney disease, cardiovascular disease, arthritis and NASH. Inflazome has a portfolio of orally available small molecule NLRP3 inhibitors, with lead molecules having successfully completed Phase I clinical trials, as well as several high potential earlier-stage programmes.
Inflazome has raised €55m in Venture Capital financing from leading investors Forbion, Longitude Capital, Fountain Healthcare Partners and Novartis Venture Fund.
Inflazome is headquartered in Dublin, Ireland.
About the NLRP3 Inflammasome
Activated NLRP3 acts as a ‘danger sensor’ in the body to release the pro-inflammatory cytokines IL-1β, IL-18 and induce uncontrolled, lytic cell death (pyroptosis). These processes lead to chronic inflammation, and as such, NLRP3 has been implicated in a large number of diseases.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200920005066/en/
Contact information
Inflazome
Dr Jeremy Skillington | VP Business Development
E: j.skillington@inflazome.com
Media:
FTI Consulting
UK & International | Ciara Martin/Tim Stamper
T: +44 20 37271000
Ireland & International | Jonathan Neilan/Patrick Berkery
T: +353 86 602 5988
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Clearlake Capital Announces Partnership with Databricks to Advance AI-Enabled Investing and Portfolio Value Creation14.7.2026 17:00:00 EEST | Press release
Clearlake Capital Group, L.P. ("Clearlake"), a global investment firm managing integrated platforms spanning private equity, liquid and private credit, and other related strategies, today announced a partnership with Databricks, the Data and AI company, and West Monroe, a global business and technology consulting firm, to accelerate Clearlake’s portfolio companies’ adoption of data, analytics, and AI capabilities. Through the collaboration, Clearlake aims to connect investment, operational, financial, and portfolio data in a secure and scalable environment that accelerates enterprise-wide adoption of AI, drives productivity, and delivers measurable outcomes across the investment lifecycle from deal origination and due diligence to portfolio monitoring and value creation. By pairing cutting-edge technology with deep operational support, the partnership endeavors to help Clearlake’s portfolio companies stay ahead of industry disruption and build durable competitive advantage. “Data and A
Andersen Consulting Deepens Advisory Solutions in Turkey with ODS Consulting Group14.7.2026 16:30:00 EEST | Press release
Andersen Consulting adds collaborating firm ODS Consulting Group, enhancing its platform across digital transformation, talent strategy, and operational advisory services. Founded in 2008 and headquartered in Turkey, ODS Consulting Group provides advisory services to organizations seeking growth, talent, and investment opportunities in Turkey and international markets. The firm supports clients through international business development and export consulting, recruitment and talent management solutions, and investment advisory services, helping businesses expand operations, access new markets, attract qualified talent, and navigate the Turkish business landscape. With a multidisciplinary approach and deep local expertise, ODS delivers tailored strategies that drive sustainable growth and long-term value creation. “Since our founding, we have focused on helping organizations build sustainable growth through a combination of strategic insight and practical execution,” said Onur Seçkin, c
IAMPHENOM Europe 2026 Speaker Lineup Focuses on Practitioners Redesigning HR Operations with AI, Agents and Automation14.7.2026 16:30:00 EEST | Press release
Phenom, the leader in applied AI built to redesign work operations for hiring faster, developing better and retaining longer, today announced the first wave of speakers for IAMPHENOM Europe 2026, the only applied AI event dedicated to human resources taking place on 4-5 November in Paris, France. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260714617871/en/ Phenom today announced the first wave of speakers for IAMPHENOM Europe 2026, the only applied AI event dedicated to human resources taking place on 4-5 November in Paris, France. At the two-day in-person event, HR professionals, talent acquisition and talent management leaders, HRIT teams and C-suite executives will experience unparalleled immersive AI learning and networking. Attendees will gain actionable strategies from the organisations already using agents and automation to improve work operations and strengthen hiring, development and retention, while connecting w
RealPage Acquires Cherre, Creating a Trusted AI-Powered Intelligence Platform Across the Full Real Estate Capital Stack14.7.2026 16:03:00 EEST | Press release
RealPage, Inc., a leading provider of AI-enabled software and data analytics to the real estate industry, today announced it has completed its acquisition of Cherre, a real estate data intelligence company trusted by institutional owners, investment managers, and operators worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260714560587/en/ RealPage now with Cherre. "AI can transform real estate only if it understands real estate," said Dirk Wakeham, President and Chief Executive Officer of RealPage. "Cherre has built the kind of trusted, governed intelligence that institutional owners and asset managers depend on. Bringing that expertise into RealPage means every customer, whether they manage one property or a global portfolio, gets access to a stronger, more trustworthy foundation for their decisions.” "We've always believed real estate organizations can't make confident decisions on data alone. They need a trusted,
Statement on Terminating the Letter of Intent With AI Financial Corporation14.7.2026 16:00:00 EEST | Press release
Statement from Matthew Nicoletti, Chief Strategy Officer, Perpetuals.com (Nasdaq: PDC), on the proposed transaction with AI Financial Corporation. “Perpetuals has decided not to further pursue the acquisition of AI Financial Corporation’s subsidiary Alt5 Sigma Canada, Inc. and the earlier letter of intent has been terminated.” About Perpetuals.com Ltd Perpetuals.com Ltd (Nasdaq: PDC) is a fintech company developing AI-powered trading products and prediction markets, with a global footprint across the United States, Europe, and Asia. Its mission is to reduce risk through empowering retail users with intuitive, secure, and efficient trading experiences that span the world’s capital markets. UpsideOnly, the company's flagship consumer product, is the first risk-free trading platform, pairing human market insight with proprietary BayesShield AI so users can share in trading profits without ever risking their own money. Perpetuals’s proprietary AI system, BayesShield AI, combines advanced A
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom